Moulopoulos LA et al. – The study shows that symptomatic myeloma patients with a diffuse Magnetic Resonance Imaging (MRI) pattern at diagnosis show very often high risk cytogenetic abnormalities and are benefiting from upfront novel agent–based therapies. Diffuse MRI pattern in combination with high risk cytogenetics and ISS–3 can identify a subset of myeloma patients with very poor prognosis who may need innovative treatment strategies and possibly more aggressive therapies. [more...]
© 2015 M3 USA Corporation. ALL Rights Reserved.